How Eli Lilly's GLP-1 Boom Changed Indianapolis

Most American cities experience a drug boom as a news story. Indianapolis experienced it as a payroll, a construction schedule, a tax base and a skyline.

Eli Lilly has been headquartered on the near south side of Indianapolis since 1876. In November 2025 it became the first drugmaker in the world worth $1 trillion, a milestone analysts attributed almost entirely to one molecule: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management [1].

This page is about what that did to the place it came from.

How big is Lilly inside Indiana?

In May 2026 the Indiana Business Research Center at Indiana University’s Kelley School of Business published a study measuring exactly this. The numbers are large enough that they are worth reading slowly [2]:

• About 14,700 people work directly for Lilly in Indiana.
• Counting suppliers and the spending those workers do, Lilly supports about 47,520 jobs statewide - an employment multiplier of 3.14, meaning every Lilly job supports about 2.14 more. (Lilly’s operating budget alone accounts for 46,600 of those jobs, at a multiplier of 3.17.)
• Average compensation per supported job: about $142,130, roughly 70% above the Indiana average.
• Direct GDP contribution: about $15.6 billion, or 2.7% of Indiana’s economy. Total impact: about $20.7 billion, or 3.6%.
• State tax revenue generated: about $520 million. Local tax revenue: about $260 million.
• Lilly accounts for roughly 70% of Indiana’s pharmaceutical manufacturing GDP and about 72% of its pharmaceutical manufacturing employment.

Adding the LEAP district operations Lilly expects to be running by 2030, the study projects about 52,400 supported jobs and nearly $22.5 billion of GDP impact, measured in 2026 dollars.

To put it plainly: one company is now more than a thirtieth of an entire state’s economy, and it employs the best-paid workers in it.

What is the LEAP district, and why does everyone in Indiana talk about it?

Because it is the biggest thing being built in the state.

The LEAP Research and Innovation District sits in Lebanon, Indiana, in Boone County, about 30 miles northwest of downtown Indianapolis. The Indiana Economic Development Corporation assembled more than 1,500 acres for it, and Lilly is the anchor.

Lilly has committed roughly $13 billion there, across three sites: Lilly Lebanon Advanced Therapies, an active pharmaceutical ingredient plant, and a facility Lilly calls the Medicine Foundry. On May 6, 2026, the company added another $4.5 billion across two of the three [3].

Chief executive David Ricks was direct about the scale: “When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home” [3].

The products named for the Lebanon campus are Zepbound, Mounjaro, the oral medicine Foundayo and the investigational retatrutide. In other words, the largest industrial project in modern Indiana history exists because of demand for weight and diabetes medicines.

The construction alone is an economy. The IU study estimates the LEAP build supports an average of about 9,470 construction jobs a year, peaking near 18,630 in 2026 [2].

How much has Lilly spent in Indiana overall?

More than $21 billion in capital expansion since 2020, according to Lilly’s May 2026 announcement, a figure the Indiana Economic Development Corporation repeated in its own monthly roundup [3][4]. Separately, Lilly has spent as much as $1.8 billion upgrading its near-downtown Indianapolis research and manufacturing operations.

None of that spending was in anyone’s plan before tirzepatide existed.

What has this done to Indianapolis itself?

Indiana University’s 2026 forecast for the Indianapolis metro reads like a document about a company town that got very lucky [5]:

• Life, physical and social science occupations grew 17.1% in a single year (May 2023 to May 2024).
• Biomedical engineer employment rose 127%, microbiologists 50%, biological technicians 42%.
• Metro employment grew 1.1% year over year, against 0.4% for Indiana as a whole.
• Chemical manufacturing, which in Indiana is dominated by pharmaceuticals, grew 6.0%; professional and scientific services grew 4.8%.
• Meanwhile technology employment fell 5.2% and leisure and hospitality fell 1.8%.

The forecast projects 1.5% to 2.0% real GDP growth for the metro in 2026, ahead of Indiana’s expected 1.0%.

Downtown, the construction list is long and only partly Lilly’s: a $4.3 billion IU Health campus, a $780 million hotel, a $600 million conversion of the old Circle Centre mall, a $227 million City Market redevelopment [5]. Commercial real estate reports now cite Lilly at about 13,298 local employees as the anchor of the region’s life sciences base. Bank of America research in February 2026 named Indianapolis one of the fastest-growing large US metros.

A fair caution: correlation is not the whole story. Indianapolis was growing before tirzepatide, and multifamily and retail construction respond to many things at once. What the data supports is that the pharmaceutical sector pulled harder than anything else in the local economy over this period.

How does the share price reach Indiana nonprofits?

Through an institution most Americans have never heard of.

Lilly Endowment Inc. is a legally separate Indianapolis philanthropy, governed independently of the company, that holds a large block of Lilly stock. As the share price climbed on tirzepatide sales, so did the Endowment’s balance sheet.

By the end of 2024 the Endowment had already become the largest private foundation in the United States, with about $79.9 billion in assets against the Gates Foundation’s $77.2 billion [6]. On November 25, 2025, as Lilly’s shares hit records, Bloomberg reported the Endowment as the first US foundation to cross $100 billion, on a holding of 92.5 million Lilly shares - about 10.3% of the company - then worth roughly $102 billion [7][16]. The Endowment’s own accounting puts its total assets at nearly $106 billion at the end of 2025 [17].

That money is spent mostly in Indiana. The Endowment’s GIFT IX initiative awarded $135.25 million to Indiana community foundations in 2025, in grants ranging from $500,000 to $15 million [8]. It committed $25 million to an Indiana Natural Disaster Fund after 2026 storms and flooding.

So the chain runs: an American takes Zepbound, Lilly’s revenue rises, the stock rises, an endowment in Indianapolis gets larger, and a community foundation in a small Indiana county has more to give away. It is an unusually short chain for something that big.

Where else is Lilly building, and why does that matter to Indiana?

Because Indiana is no longer the only place.

On February 26, 2025, Lilly announced $27 billion for four new US manufacturing sites, calling it the largest pharmaceutical manufacturing investment in US history, with a projected 3,000-plus permanent jobs and nearly 10,000 construction jobs [9]. Then the sites landed, one by one, each becoming a major local story somewhere else:

• Goochland County, Virginia, about $5 billion, announced September 16, 2025.
• Houston, Texas, more than $6.5 billion at Generation Park, announced September 23, 2025. Governor Greg Abbott’s office cited more than 600 permanent jobs [10].
• Huntsville, Alabama, more than $6 billion on a 260-acre site, announced December 9, 2025, with about 450 permanent jobs and roughly 3,000 construction jobs. The city called it the largest private industrial investment in Alabama history [11].
• Fogelsville, Pennsylvania, in the Lehigh Valley, $3.5 billion with about 850 permanent jobs, announced January 30, 2026 - the largest life sciences investment in Pennsylvania history, with about $100 million in state support [12].

For Indiana, that is both reassuring and not. Lilly is still expanding at home. But the company’s manufacturing map is now national, and the competition for the next plant is a bidding war among governors.

What could go wrong?

Three things, and Indiana officials talk about all of them.

Concentration. Roughly 70% of the state’s pharmaceutical GDP comes from one company, and that company’s growth currently rests on one drug class. If tirzepatide demand slows - through competition, pricing pressure, or a shift to pills - a large share of Indiana’s recent growth slows with it.

Pricing pressure is already here. Lilly cut Zepbound’s cash price twice, to $299 for the lowest dose by December 2025, and agreed with the Trump administration in November 2025 to a $50 Medicare copay and TrumpRx pricing in exchange for three years of tariff relief. Revenue per patient is falling even as patient numbers rise.

Workforce. Indianapolis Business Journal reporting has described Lilly’s growth testing the state’s workforce development system, with hundreds of open positions in Indianapolis and Lebanon at a time. A $4.5 billion plant needs people who can run it.

Indiana’s answer arrived on March 17, 2026, when Governor Mike Braun announced a $1 billion commitment to agriculture and life sciences with a stated goal of 100,000 high-wage jobs over ten years [13]. That job number is a state projection, not a measured outcome, and should be read as one. But the strategic logic is clear enough: build an industry around the company, so the state is not betting everything on a single molecule.

What does the boom look like right now?

Lilly’s second quarter of 2026 gives the shape of it: revenue of $23.0 billion, up 48%, with Mounjaro at $9.943 billion worldwide and Zepbound at $4.928 billion - close to 65% of the company’s revenue from one molecule [14]. Full-year guidance was raised to $85 billion to $87 billion.

The market value has hovered around $1 trillion through 2026, with trackers putting it between roughly $1.05 trillion and $1.11 trillion in late August and early September, depending on the source and the day [15]. That is a volatile number: over the preceding twelve months Lilly’s share price ranged from about $712 to about $1,293. Lilly employed about 50,000 people worldwide at the end of 2025.

A city of about 900,000 people is attached to that. Whatever happens to the GLP-1 market next happens to Indianapolis too.

Sources

1. BioPharma Dive, “Eli Lilly becomes first drugmaker to hit $1 trillion in market value,” November 21, 2025. https://www.biopharmadive.com/news/eli-lilly-1-trillion-pharmaceutical-market-value-obesity/721819/
2. Indiana Business Research Center, Kelley School of Business, Indiana University, “Eli Lilly and Company’s Impact,” May 2026. https://www.ibrc.indiana.edu/studies/Lilly_Report-2026.pdf
3. Eli Lilly, “Lilly commits additional $4.5 billion across Indiana manufacturing,” May 6, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing
4. Indiana Economic Development Corporation, “Indiana is open for business: May’s jobs and wages wins,” May 29, 2026. https://iedc.in.gov/events/news/details/2026/05/29/indiana-is-open-for-business-may-s-jobs-and-wages-wins
5. Indiana Business Research Center, “Indianapolis-Carmel-Greenwood Forecast 2026.” https://www.ibrc.indiana.edu/ibr/pre/outlook/indianapolis-carmel.html
6. Investing.com, “Eli Lilly endowment tops $100 billion,” 2025. https://www.investing.com/news/stock-market-news/eli-lilly-endowment-tops-100-billion-93CH-4378180
7. TipRanks, “Eli Lilly’s endowment becomes the largest in the U.S. with $100 billion of assets,” 2025. https://www.tipranks.com/news/eli-lillys-lly-endowment-becomes-the-largest-in-the-u-s-with-100-billion-of-assets
8. Lilly Endowment Inc., “GIFT IX,” 2025. https://lillyendowment.org/gift-ix/
9. Eli Lilly, “Lilly plans to more than double U.S. manufacturing investment since 2020,” February 26, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-plans-more-double-us-manufacturing-investment-2020
10. Office of the Governor of Texas, “Governor Abbott announces new Eli Lilly manufacturing investment in Harris County,” September 23, 2025. https://gov.texas.gov/news/post/governor-abbott-announces-new-eli-lilly-manufacturing-investment-in-harris-county
11. Office of the Governor of Alabama, “Governor Ivey announces Lilly plans $6 billion advanced manufacturing plant in Huntsville,” December 9, 2025. https://governor.alabama.gov/newsroom/2025/12/governor-ivey-announces-pharmaceutical-giant-lilly-plans-6-billion-advanced-manufacturing-plant-in-huntsville/
12. Office of the Governor of Pennsylvania, “Governor Shapiro secures historic $3.5 billion investment from Lilly,” January 30, 2026. https://www.pa.gov/governor/newsroom/2026-press-releases/governor-shapiro-secures-historic—3-5-billion-investment-from-l
13. Indiana Capital Chronicle, “Braun unveils $1 billion agriculture and life sciences initiative,” March 17, 2026. https://indianacapitalchronicle.com/2026/03/17/braun-unveils-1-billion-agriculture-and-life-sciences-initiative/
14. Eli Lilly, second-quarter 2026 financial results, August 5, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full
15. Stock Analysis, Eli Lilly market capitalization, September 11, 2026. https://stockanalysis.com/stocks/lly/market-cap/
16. Bloomberg, “Lilly Endowment is first to hit $100 billion mark on stock surge,” November 25, 2025. https://www.bloomberg.com/news/articles/2025-11-25/lilly-endowment-is-first-to-hit-100-billion-mark-on-stock-surge
17. Lilly Endowment Inc., “History and founders” (end-2025 assets). https://lillyendowment.org/about/history-and-founders

This page describes an economy, not a treatment. It contains no medical advice and no investment advice.